Abstract
A new 1,4-benzothiazepine derivative, JTV519 (JTV), has strong protective effects against isoproterenol-induced myocardial injury. We investigated the effects of JTV on Ca2+ overload and on functional recovery during ischemia/reperfusion in isolated coronary-perfused rat hearts. After 30 minutes of reperfusion following 30 min of global ischemia, the % recovery of LV developed pressure was improved in a concentration-dependent manner when JTV (0.3-3.0 μM) was administered either 5 min before induction of ischemia or for 5 min at the time of reperfusion only JTV showed a negative inotropic effect only at concentrations above 3.0 μM. In indol-loaded isolated heart preparations, 0.3 μM JTV did not affect the preischemic systolic or diastolic Ca2+ levels of the Ca2+ transient as measured by the ratio of 2-wavelength fluormetry (R405/500). In contrast, it significantly reduced the increase in the ratio in the postischemic reperfusion period (% change of R405/500 from baseline: JTV(-), by 42.7 ± 3.2%; JTV(+), by 18.4 ± 9.1%, p < 0.05). In isolated rat ventricular myocytes with a standard patch-clamp method, we further tested the interaction of JTV with the L-Type Ca2+ channel (ICa). The % inhibition of the peak current of ICa was 6.2 ± 0.8% at 0.3 μM (p = n.s.), 22.0 ± 3.3% at 1.0 μM (p < 0.05), and 59.6 ± 1.4% at 3.0 μM (p < 0.01). Thus, the marked cardioprotection due to JTV at 0.3 μM may not be solely attributed to its inhibitory effect on the transsarcolemmal Ca2+ influx through ICa. In conclusion, JTV519 is a novel pharmacological agent that has been demonstrated for the first time to have clinical potential for the treatment of acute coronary syndrome by its efficacy in administration at the time of reperfusion, by its suppression of reperfusion-related intracellular Ca2+ overload with no significant interaction with ICa, and by its subsequent ability of strong myocardial protection.
Similar content being viewed by others
References
Kihara Y, Grossman W, Morgan, JP. Circ Res 1989;65:1029-1044.
Lee HC, Mohabir R, Smith N, Franz MR, Clusin WT. Circulation 1988;78:1047-1059.
Amende I, Bentivegna LA, Zeind AJ, Wenzlaff P, Grossman W, Morgan JP. J Clin Invest 1992;89:2060-2065.
Watts JA, Maiorano LJ, Mariorano PC. J Mol Cell Cardiol 1985;17:797-804.
Kaneko N. Drug Develp Res 1994;33:429-438.
Morii I, Kihara, Y, Inoko M, Sasayama S. Hypertension 1998;31:949-960.
Morii I, Kihara Y, Konishi T, Inubushi T, Sasayama S. Jpn Circ J 1996;8:593-603.
Josephson RA, Silverman HS, Lakatta EG, Stern MD, Zweier JL. J Biol Chem 1991;266:2354-2361.
Takagi S, Kihara Y, Sasayama S, Mitsuiye T. Am J Physiol 1998;274:R348-R356.
Hampton TG, Amende I, Travers KE, Morgan JP. Am J Physiol 1998;274:H1821-H1827.
Kusuoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E. J Clin Invest 1987;79:950-961.
Meissner A, Morgan JP. Am J Physiol 1995;268:H100-H111.
Atar, D, Gao WD, Marban E. J Mol Cell Cardiol 1995;27:783-791.
Marban E. Circulation 1991;83:681-688.
Tani M. Annu Rev Physiol 1991;52:543-559.
Raynal P, Pollard HB. Biochim Biophys Acta 1994;1197:63-93.
Rojas E, Pollard HB, Haipler HT, Parra C, Burns AL. J Biol Chem 1990;265:21207-21215.
Kaneko N, Matsuda R, Toda M, Shimamoto K. Biochim Biophys Acta 1997;1330:1-7.
Inagaki K, Kihara Y, Hayashida W, Sasayama S. J Am Coll Cardiol 1999;33(suppl A):387A.
Speechly-Disk ME, Grover GJ, Yellon DM. Circ Res 1995;77: 1030-1035.
Hu K, Duan D, Li GR, Nattel S. Circ Res 1996;78:492-498.
Ito K, Sato T, Abe T, Li G, Arita M. Jpn Circ J 62(suppl I): 150.
Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. Jpn J Pharmacol 1999;79:275-281.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inagaki, K., Kihara, Y., Izumi, T. et al. The Cardioprotective Effects of a New 1,4-Benzothiazepine Derivative, JTV519, on Ischemia/Reperfusion-Induced Ca2+ Overload in Isolated Rat Hearts . Cardiovasc Drugs Ther 14, 489–495 (2000). https://doi.org/10.1023/A:1007884905461
Issue Date:
DOI: https://doi.org/10.1023/A:1007884905461